Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - European journal …, 2018 - pubmed.ncbi.nlm.nih.gov
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - EUROPEAN …, 2018 - iris.uniupo.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - EUROPEAN JOURNAL …, 2018 - cris.unibo.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
M Ortalli, A Ilari, G Colotti, I Ionna, T Battista, A Bisi… - 2018 - cabidigitallibrary.org
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
M Ortalli, A Ilari, G Colotti, I De Ionna… - European Journal of …, 2018 - europepmc.org
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - European Journal of …, 2018 - research.uniupo.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - EUROPEAN …, 2018 - iris.uniroma1.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - EUROPEAN …, 2018 - iris.uniroma1.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
M Ortalli, A Ilari, G Colotti, I De Ionna… - European Journal of …, 2018 - research.uniupo.it
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …